Drugs and ablation in the treatment of supraventricular tachyarrhythmias in children.
Identifieur interne : 001702 ( PubMed/Corpus ); précédent : 001701; suivant : 001703Drugs and ablation in the treatment of supraventricular tachyarrhythmias in children.
Auteurs : E. VillainSource :
- Current opinion in pediatrics [ 1040-8703 ] ; 1993.
English descriptors
- KwdEn :
- MESH :
- drug therapy : Tachycardia, Supraventricular.
- surgery : Tachycardia, Supraventricular, Wolff-Parkinson-White Syndrome.
- Catheter Ablation, Child, Humans.
Abstract
The vast majority of children who have symptoms (ie, cardiac failure, palpitations, dizziness) due to supraventricular tachycardias are successfully managed by medical treatment. Antiarrhythmic drug therapy may be complicated by side effects or become ineffective so that radiofrequency catheter ablation, which destroys the myocardial structure responsible for arrhythmias, can now offer an attractive option to lifelong drug therapy. Immediate results for supraventricular tachycardias due to a reentry mechanism or to an atrial ectopic focus are good, with a success rate over 80% and rare immediate complications. However, the long-term sequelae of the procedure on the growing heart have not been established and the risk of subsequent atrial and ventricular arrhythmias must be considered in young patients. For this reason, I believe that today, radiofrequency ablation should be reserved for young patients who have life-threatening symptoms or who have arrhythmias that are refractory to medical treatment, and for older patients who will need a lifelong drug therapy.
PubMed: 8287085
Links to Exploration step
pubmed:8287085Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Drugs and ablation in the treatment of supraventricular tachyarrhythmias in children.</title><author><name sortKey="Villain, E" sort="Villain, E" uniqKey="Villain E" first="E" last="Villain">E. Villain</name><affiliation><nlm:affiliation>Hôpital Necker Enfants-Malades, Paris, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1993">1993</date><idno type="RBID">pubmed:8287085</idno><idno type="pmid">8287085</idno><idno type="wicri:Area/PubMed/Corpus">001702</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001702</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Drugs and ablation in the treatment of supraventricular tachyarrhythmias in children.</title><author><name sortKey="Villain, E" sort="Villain, E" uniqKey="Villain E" first="E" last="Villain">E. Villain</name><affiliation><nlm:affiliation>Hôpital Necker Enfants-Malades, Paris, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Current opinion in pediatrics</title><idno type="ISSN">1040-8703</idno><imprint><date when="1993" type="published">1993</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Catheter Ablation</term><term>Child</term><term>Humans</term><term>Tachycardia, Supraventricular (drug therapy)</term><term>Tachycardia, Supraventricular (surgery)</term><term>Wolff-Parkinson-White Syndrome (surgery)</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Tachycardia, Supraventricular</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Tachycardia, Supraventricular</term><term>Wolff-Parkinson-White Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Catheter Ablation</term><term>Child</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The vast majority of children who have symptoms (ie, cardiac failure, palpitations, dizziness) due to supraventricular tachycardias are successfully managed by medical treatment. Antiarrhythmic drug therapy may be complicated by side effects or become ineffective so that radiofrequency catheter ablation, which destroys the myocardial structure responsible for arrhythmias, can now offer an attractive option to lifelong drug therapy. Immediate results for supraventricular tachycardias due to a reentry mechanism or to an atrial ectopic focus are good, with a success rate over 80% and rare immediate complications. However, the long-term sequelae of the procedure on the growing heart have not been established and the risk of subsequent atrial and ventricular arrhythmias must be considered in young patients. For this reason, I believe that today, radiofrequency ablation should be reserved for young patients who have life-threatening symptoms or who have arrhythmias that are refractory to medical treatment, and for older patients who will need a lifelong drug therapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8287085</PMID><DateCreated><Year>1994</Year><Month>02</Month><Day>22</Day></DateCreated><DateCompleted><Year>1994</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2005</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1040-8703</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>5</Issue><PubDate><Year>1993</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Current opinion in pediatrics</Title><ISOAbbreviation>Curr. Opin. Pediatr.</ISOAbbreviation></Journal><ArticleTitle>Drugs and ablation in the treatment of supraventricular tachyarrhythmias in children.</ArticleTitle><Pagination><MedlinePgn>606-10</MedlinePgn></Pagination><Abstract><AbstractText>The vast majority of children who have symptoms (ie, cardiac failure, palpitations, dizziness) due to supraventricular tachycardias are successfully managed by medical treatment. Antiarrhythmic drug therapy may be complicated by side effects or become ineffective so that radiofrequency catheter ablation, which destroys the myocardial structure responsible for arrhythmias, can now offer an attractive option to lifelong drug therapy. Immediate results for supraventricular tachycardias due to a reentry mechanism or to an atrial ectopic focus are good, with a success rate over 80% and rare immediate complications. However, the long-term sequelae of the procedure on the growing heart have not been established and the risk of subsequent atrial and ventricular arrhythmias must be considered in young patients. For this reason, I believe that today, radiofrequency ablation should be reserved for young patients who have life-threatening symptoms or who have arrhythmias that are refractory to medical treatment, and for older patients who will need a lifelong drug therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Villain</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hôpital Necker Enfants-Malades, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Pediatr</MedlineTA><NlmUniqueID>9000850</NlmUniqueID><ISSNLinking>1040-8703</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017115" MajorTopicYN="Y">Catheter Ablation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013617" MajorTopicYN="N">Tachycardia, Supraventricular</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014927" MajorTopicYN="N">Wolff-Parkinson-White Syndrome</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>24</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8287085</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001702 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001702 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:8287085
|texte= Drugs and ablation in the treatment of supraventricular tachyarrhythmias in children.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:8287085" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |